Identifying the common barriers to optimal COPD care in Japan, Canada, England, and Germany through Evidenced Care Pathways
Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark
Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits
Point-of-care tests for infectious diseases: Barriers to implementation across three London teaching hospitals
Modelling the burden of non-muscle-invasive bladder cancer in Europe
Mapping the diagnostic pathway for breast cancer in England and comparison to Europe
Cervical screening and HPV testing: Opportunities for rapid tests
We explored the use of a rapid, on-demand human papillomavirus (HPV) test. Interviews with UK experts revealed that a co-located, on-demand HPV test following cytology could reduce the time to cervical screening results by up to a week, with a near-patient primary HPV test followed by cytology triage could radically change the testing paradigm. A follow-up tool we built in Excel was used to understand cervical screening burden and HPV testing across Europe.
The cost of pelvic inflammatory disease and potential cost-savings of chlamydia screening
We worked with clinicians from St Georges University who had published a trial estimating the incidence of pelvic inflammatory disease (PID) among women screened and unscreened for chlamydia. Patient data was analysed, and the average cost of managing PID was estimated to be £163 in community and hospital settings, and that over £60,000 could be saved in London alone from screening for chlamydia. This paper has been cited widely and results have informed policy and further modelling studies.
Providing integrated HIV treatment and care for stable patients in general practice
How can European countries improve cervical cancer prevention for women?
